RADIATION ONCOLOGY RESIDENCY PROGRAM Competency Evaluation of Resident

Compet	elicy Evalu	ation of Ne	sideiit	
Resident's Name:				
Rotation:	PHYS 703: CI	inical Rotation	2	
Inclusive dates of rotation:	Feb. 26, 2010	6 – Aug. 25, 20	16	
Director or Associate Director:				
Evaluation criteria	Not Competent	Marginally Competent	Fully Competent	Explanatory Notes & Mentor Signature
Treatment Techniques				
Demonstrates understanding of 2D coplanar beam treatment planning				
2. Demonstrates an understanding of the placement of non-coplanar beams (3D) in external beam treatment planning				
3. Demonstrates an understanding of the following image-guided radiation therapy techniques:				
a. Planar MV imaging				
b. Planar kV imaging				
c. Cone beam computed tomography (CBCT)				
d. Ultrasound (US)				
e. Non-radiographic localization, e.g., US, surface camera, radiofrequency (RF) beacon tracking.				
4. Demonstrates an understanding of image registration techniques, e.g., rigid and deformable registration				
5. Demonstrates an understanding of site-specific techniques (photons and electrons):				
a. Performs 3D or IMRT treatment planning for breast and chest wall that includes axilla fields and the single isocenter technique				

	1		
b. Performs 3D or IMRT treatment			
planning for the brain, spine, and			
craniospinal irradiation			
c. Performs 3D or IMRT treatment			
planning for the bladder, prostate,			
and testis			
and testis			
d. Performs 3D or IMRT treatment			
planning for gynecological tumors			
e. Performs 3D or IMRT treatment			
planning for gastrointestinal			
tumors, e.g., colorectal tumors,			
tumors of the esophagus, stomach,			
and liver			
f. Performs 3D or IMRT treatment			
planning for head and neck tumors			
g. Performs 3D treatment planning			
for common lymphomas that			
includes the mantle field technique;			
h. Performs 3D treatment planning			
for skin cancers			
i. Demonstrates an understanding			
of common 3D or IMRT			
treatment planning techniques for			
pediatric cancers and performs 3D			
treatment planning for pediatric			
craniospinal irradiation			
j. Demonstrates an understanding			
of common 3D or IMRT			
treatment planning techniques for			
sarcoma of the trunk and			
extremities			
k. Performs 3D or IMRT treatment			
planning for the lungs,			
mediastinum, and thoracic region			
,			
Treatment Planning			
1 Doom properties			
1. Beam properties			
a. Demonstrates an understanding of			
photon and electron percent depth			
dose in tissue and other media			
b. Demonstrates an understanding of			
electron ranges (Rp, R80, R90, and			
dmax) for different energies			
c. Demonstrates an understanding of		 	
proton percent depth dose in			
tissue and other media and			
proton ranges for different			
-			
energies, e.g., stopping and			
scattering power and range			

	1		
d. Demonstrates an understanding of			
the potential uncertainties in dose			
deposition in proton radiotherapy			
e. Demonstrates an understanding of			
the flatness and symmetry of			
photon and electron beams			
f. Demonstrates an understanding of			
the differences between source-to-			
axis distance (SAD) and source-to-			
skin distance (SSD) treatments;			
g. Demonstrates an understanding of			
the applicability of electron and			
photon therapy with regard to			
disease, depth, and critical normal			
structures			
h. Discusses the impact of dose and			
fractionation on normal and tumor			
tissues			
i. Demonstrates an understanding			
of the impact of beam quality			
(e.g., linear energy transfer [LET])			
on the relative biological			
effectiveness (RBE) of different			
forms of ionizing radiation (e.g.,			
electrons, photons, and protons)			
j. Discusses the uncertainties related			
to electron and photon therapy			
(e.g., in terms of physics, biology,			
machine and patient setup			
accuracy) and how they may be			
detected and mitigated during the			
planning and delivery process.			
_			
2. Beam modifiers			
a. Demonstrates an understanding			
of the effect of beam modifiers			
(e.g., wedges, compensators) on			
the dosimetric characteristics of			
the incident beam			
b. Demonstrates an understanding			
of wedges (wedge angle, hinge			
angle) and the different types of			
wedges used clinically (physical,			
universal, dynamic)			
c. Demonstrates an understanding			
of the design of the different			
commercially available multileaf			
collimators (MLCs)			
d. Demonstrates an understanding of			
blocking and shielding for therapy			
beams			
2001113			

e. Demonstrates an understanding of the use of custom bolus		
f. Demonstrates an understanding of the design and use of tissue compensators.		
3. Treatment simulation techniques		
a. Demonstrates an understanding of common patient-positioning and immobilization devices		
b. Demonstrates an understanding of when and how to use specific treatment devices for specific treatments		
c. Discusses how to account for beam attenuation from patient-positioning and immobilization devices in treatment planning.		
4. Tumor localization and normal tissue anatomical contouring		
a. Performs structure delineation on CT, MRI, PET, PET/CT, SPECT, or SPECT/ CT data sets		
b. Demonstrates an understanding of target volume determination, including the design of ICRU target structures (involving concepts such as gross tumor volume [GTV], clinical target volume [CTV], internal target volume [ITV], planning target volume [PTV], and planning organ at risk volume [PRV]);		
c. Demonstrates an understanding of how 4D data is used for target definition and relevant radiation treatment prescription parameters such as GTV, PTV, CTV, and ITV		
d. Demonstrates an understanding of the role of maximum intensity projection (MIP) images in the treatment planning process		
e. Demonstrates an understanding of the role of digitally reconstructed radiographs (DRRs) in the treatment planning process		
f. Demonstrates an understanding of and performs image registration and fusion of data sets for modalities such as CT/CT, CT/MRI, and CT/PET; deformable		

registration; and image/dose		
registration.		
5. Plan evaluation. Defines and		
discusses each of the following		
_		
treating planning evaluation tools,		
including their limitations:		
a. Dose volume histograms (V(dose),		
D(volume), mean dose; cumulative		
and differential)		
b. Conformity index		
c. Homogeneity index		
d. Biological evaluators (e.g.,		
generalized equivalent uniform		
dose [gEUD], equivalent uniform		
dose [EUD], normal tissue		
complication probability [NTCP],		
and tumor control probability		
[TCP]).		
Discusses dose tolerances for various		
normal tissue structures along with		
relevant volume effects.		
Intensity-modulated Radiation		
Therapy (IMRT)		
Therapy (HVIIVT)		
1. Inverse planning		
a Domonaturates an unidomaten dina		
a. Demonstrates an understanding		
of the use of objective functions		
for IMRT optimization		
b. Demonstrates an understanding of		
the optimization processes involved		
in inverse planning		
c. Performs inverse planning		
optimization for a variety of		
treatment sites in sufficient number		
to become proficient in the		
optimization process (see Section		
4.5.2.1)		
d. Demonstrates an understanding		
of commonly used planning		
procedures and guidelines as well		
as optimization and dose		
calculation algorithms.		
2. IMRT/volumetric modulated arc		
1		
therapy (VMAT) delivery		
a. Demonstrates an understanding of		
various IMRT delivery techniques		
(e.g., compensators, static field		
IMRT, rotational delivery		

	 Τ	
techniques) and their relative advantages and disadvantages		
b. Explains the differences between dynamic multileaf collimator (DMLC) and segmental multileaf collimator (SMLC) leaf sequencing algorithms in terms of delivery parameters and dose distributions		
c. Participates in IMRT or VMAT delivery for patients with a variety of treatment sites and demonstrates an understanding of the techniques and requirements for patient setup, immobilization, and localization.		
Monitor Unit (MU) Calculations		
Demonstrates an understanding and performs derivation of the following factors:		
a. Percent depth dose (PDD)		
b. Tissue-air ratio (TAR)		
c. Tissue-maximum ratio (TMR)		
d. Tissue-phantom ratio (TPR)		
e. Scatter factors (i.e., Sc, Sp, Scp)		
f. Off-axis factors		
g. Inverse square factors		
h. Calibration factor (monitor unit [MU] reference conditions)		
i. Standard wedge factors		
j. Virtual and dynamic wedge factors		
k. Compensator factors		
I. Tray and other insert factors		
2. Performs manual MU calculations for photon or electron beams of the following configurations:		

	<u> </u>	1	<u> </u>	
a. SSD setup				
b. SAD setup				
c. Extended distance setup				
d. Off-axis calculation points				
e. Rotational beams				
Demonstrates an understanding of and performs MU calculations using heterogeneity corrections				
Quality Assurance (QA)				
Performs treatment plan verification involving:				
a. Review of patient history (such as prior radiotherapy and potential overlap with current treatment), disease, course of treatment, and dose prescription				
b. Review of appropriateness of the treatment plan and dose distribution to achieve the goals of the treatment course				
c. Review of simulation (e.g., patient positioning and immobilization), planning, imaging, and treatment field parameters				
d. Review of monitor unit or time calculations				
e. Review of images to be used for patient positioning or monitoring				
f. Review of transfer of plan parameters and images to record and verify system and any other patient monitoring systems				
2. Performs IMRT QA:				
a. Demonstrates an understanding of the appropriate level of quality control tests for IMRT				
b. Demonstrates an understanding of commonly used QA procedures and guidelines, delivery and dosimetry equipment, and QA analysis techniques				

c. Calculates verification plans within the treatment planning system along with independent checks using secondary MU calculation software d. Performs IMRT delivery QA measurements using 2D/3D array, film, or ion chamber techniques, an activity that includes analysis of results and determination of passing criteria (which will involve familiarity with the concept of gamma analysis) e. Performs and analyzes MIC QA measurements designed for accelerators used for IMRT; and f. Reviews individual patient-specific QA results with staff physicists and physicians 3. Performs ongoing review of treatment records (e.g., chart checks, review of treatment or setup images), including verification of delivered treatments 4. Demonstrates an understanding of the following components of an in vivo dosimetry program: a. Acceptance, commissioning, calibration, and ongoing quality assurance procedures for in vivo dosimetry systems for patient-specific measurement (c. Limitations of specific in vivo dosimetry systems for patient-specific measurement c. Limitations of specific in vivo dosimetry systems 5. Demonstrates familiarity with the dose limits relevant to sensitive structures outside of the treatment field (e.g., gonads, fetus, and electronic implanted device such as cardiac pacemaker and/or defibrillator) and the ability to determine the dose to these structures Special Procedures Special Procedures 1. Small field a. Stereotactic radiosurgery (SRS)		Т	п	
system along with independent checks using secondary MU calculation software d. Performs IMRT delivery QA measurements using 2D/3D array, film, or ion chamber techniques, an activity that includes analysis of results and determination of passing criteria (which will involve familiarity with the concept of gamma analysis) e. Performs and analyses MLC QA measurements designed for accelerators used for IMRT; and f. Reviews individual patient-specific QA results with staff physicists and physicians 3. Performs ongoing review of treatment records (e.g., chart checks, review of treatment or setup images), including verification of delivered treatments d. Demonstrates an understanding of the following components of an in vivo dosimetry program: a. Acceptance, commissioning, calibration, and ongoing quality assurance procedures for in vivo dosimetry systems b. Use of in vivo dosimetry systems for patient-specific measurement c. Limitations of specific in vivo dosimetry systems 5. Demonstrates familiarity with the dose limits relevant to sensitive structures outside of the treatment field (e.g., gonads, fetus, and electronic implanted device such as cardiac pacemaker and/or defibrillator) and the ability to determine the dose to these structures Special Procedures 1. Small field	-			
checks using secondary MU calculation software d. Performs IMRT delivery QA measurements using 2D/3D array, film, or ion chamber techniques, an activity that includes analysis of results and determination of passing criteria (which will involve familiarity with the concept of gamma analysis) e. Performs and analyzes MLC QA measurements designed for accelerators used for IMRT; and f. Reviews individual patient-specific QA results with staff physicists and physicians 3. Performs ongoing review of treatment records (e.g., chart checks, review of treatment or setup images), including verification of delivered treatments 4. Demonstrates an understanding of the following components of an in vivo dosimetry program: a. Acceptance, commissioning, calibration, and ongoing quality assurance procedures for in vivo dosimetry systems b. Use of in vivo dosimetry systems for patient-specific measurement c. Limitations of specific in vivo dosimetry systems 5. Demonstrates familiarity with the dose limits relevant to sensitive structures outside of the treatment field (e.g., gonads, fetus, and electronic implanted device such as cardiac pacemaker and/or defibrillator) and the ability to determine the dose to these structures Special Procedures 1. Small field	. –			
d.Performs IMRT delivery QA measurements using 2D/3D array, film, or ion chamber techniques, an activity that includes analysis of results and determination of passing criteria (which will innove familiarity with the concept of gamma analysis) e. Performs and analyzes MLC QA measurements designed for accelerators used for IMRT; and f. Reviews individual patient-specific QA results with staff physicists and physicians 3. Performs ongoing review of treatment records (e.g., chart checks, review of treatment or setup images), including verification of delivered treatments 4. Demonstrates an understanding of the following components of an in wivo dosimetry program: a. Acceptance, commissioning, calibration, and ongoing quality assurance procedures for in vivo dosimetry systems b. Use of in vivo dosimetry systems for patient-specific measurement c. Limitations of specific in vivo dosimetry systems 5. Demonstrates familiarity with the dose limits relevant to sensitive structures outside of the treatment field (e.g., gonads, fetus, and electronic implanted device such as cardiac pacemaker and/or defibrillator) and the ability to determine the dose to these structures Special Procedures 1. Small field	= -			
d. Performs IMRT delivery QA measurements using 2D/3D array, film, or ion chamber techniques, an activity that includes analysis of results and determination of passing criteria (which will involve familiarity with the concept of gamma analysis) e. Performs and analyzes MLC QA measurements designed for accelerators used for IMRT; and f. Reviews individual patient-specific QA results with staff physicists and physicians 3. Performs ongoing review of treatment records (e.g., chart checks, review of treatment or setup images), including verification of delivered treatments 4. Demonstrates an understanding of the following components of an in vivo dosimetry program: a. Acceptance, commissioning, calibration, and ongoing quality assurance procedures for in vivo dosimetry systems b. Use of in vivo dosimetry systems for patient-specific measurement c. Limitations of specific in vivo dosimetry systems 5. Demonstrates familiarity with the dose limits relevant to sensitive structures outside of the treatment field (e.g., gonads, fetus, and electronic implanted device such as cardiac pacemaker and/or defibrillator) and the ability to determine the dose to these structures Special Procedures 1. Small field				
measurements using 2D/3D array, film, or ion chamber techniques, an activity that includes analysis of results and determination of passing criteria (which will involve familiarity with the concept of gamma analysis) e. Performs and analyses MLC QA measurements designed for accelerators used for IMRT; and f. Reviews individual patient-specific QA results with staff physicists and physicians 3. Performs ongoing review of treatment records (e.g., chart checks, review of treatment or setup images), including verification of delivered treatments 4. Demonstrates an understanding of the following components of an in vivo dosimetry program: a. Acceptance, commissioning, calibration, and ongoing quality assurance procedures for in vivo dosimetry systems b. Use of in vivo dosimetry systems b. Use of in vivo dosimetry systems for patient-specific measurement c. Limitations of specific in vivo dosimetry systems 5. Demonstrates familiarity with the dose limits relevant to sensitive structures outside of the treatment field (e.g., gonads, fetus, and electronic implanted device such as cardiac pacemaker and/or defibrillator) and the ability to determine the dose to these structures Special Procedures 1. Small field				
array, film, or ion chamber techniques, an activity that includes analysis of results and determination of passing criteria (which will involve familiarity with the concept of gamma analysis) e. Performs and analyzes MLC QA measurements designed for accelerators used for IMRT; and f. Reviews individual patient-specific QA results with staff physicists and physicians 3. Performs ongoing review of treatment records (e.g., chart checks, review of treatment or setup images), including verification of delivered treatments 4. Demonstrates an understanding of the following components of an in vivo dosimetry program: a. Acceptance, commissioning, calibration, and ongoing quality assurance procedures for in vivo dosimetry systems b. Use of in vivo dosimetry systems for patient-specific measurement c. Limitations of specific in vivo dosimetry systems 5. Demonstrates familiarity with the dose limits relevant to sensitive structures outside of the treatment field (e.g., gonads, fetus, and electronic implanted device such as cardiac pacemaker and/or defibrillator) and the ability to determine the dose to these structures Special Procedures 1. Small field	*			
techniques, an activity that includes analysis of results and determination of passing criteria (which will involve familiarity with the concept of gamma analysis) e. Performs and analyzes MLC QA measurements designed for accelerators used for IMRT; and f. Reviews individual patient-specific QA results with staff physicists and physicians 3. Performs ongoing review of treatment crooks, review of treatment or setup images), including verification of delivered treatments 4. Demonstrates an understanding of the following components of an in vivo dosimetry program: a. Acceptance, commissioning, calibration, and ongoing quality assurance procedures for in vivo dosimetry systems b. Use of in vivo dosimetry systems for patient-specific measurement c. Limitations of specific in vivo dosimetry systems 5. Demonstrates familiarity with the dose limits relevant to sensitive structures outside of the treatment field (e.g., gonads, fetus, and electronic implanted device such as cardiac pacemaker and/or defibrillator) and the ability to determine the dose to these structures Special Procedures 1. Small field	_			
includes analysis of results and determination of passing criteria (which will involve familiarity with the concept of gamma analysis) e. Performs and analyzes MLC QA measurements designed for accelerators used for IMRT; and f. Reviews individual patient-specific QA results with staff physicists and physicians 3. Performs ongoing review of treatment records (e.g., chart checks, review of treatment or setup images), including verification of delivered treatments 4. Demonstrates an understanding of the following components of an in vivo dosimetry program: a. Acceptance, commissioning, calibration, and ongoing quality assurance procedures for in vivo dosimetry systems b. Use of in vivo dosimetry systems for patient-specific measurement c. Limitations of specific in vivo dosimetry systems 5. Demonstrates familiarity with the dose limits relevant to sensitive structures outside of the treatment field (e.g., gonads, fetus, and electronic implanted device such as cardiac pacemaker and/or defibrillator) and the ability to determine the dose to these structures Special Procedures 1. Small field				
determination of passing criteria (which will involve familiarity with the concept of gamma analysis) e. Performs and analyzes MLC QA measurements designed for accelerators used for IMRT; and f. Reviews individual patient-specific QA results with staff physicists and physicians 3. Performs ongoing review of treatment records (e.g., chart checks, review of treatment or setup images), including verification of delivered treatments 4. Demonstrates an understanding of the following components of an in vivo dosimetry program: a. Acceptance, commissioning, calibration, and ongoing quality assurance procedures for in vivo dosimetry systems b. Use of in vivo dosimetry systems for patient-specific measurement c. Limitations of specific in vivo dosimetry systems 5. Demonstrates familiarity with the dose limits relevant to sensitive structures outside of the treatment field (e.g., gonads, fetus, and electronic implanted device such as cardiac pacemaker and/or defibrillator) and the ability to determine the dose to these structures Special Procedures 1. Small field				
(which will involve familiarity with the concept of gamma analysis) e. Performs and analyzes MLC QA measurements designed for accelerators used for IMRT; and f. Reviews individual patient-specific QA results with staff physicists and physicians 3. Performs ongoing review of treatment records (e.g., chart checks, review of treatment or setup images), including verification of delivered treatments 4. Demonstrates an understanding of the following components of an in vivo dosimetry program: a. Acceptance, commissioning, calibration, and ongoing quality assurance procedures for in vivo dosimetry systems b. Use of in vivo dosimetry systems for patient-specific measurement c. Limitations of specific in vivo dosimetry systems 5. Demonstrates familiarity with the dose limits relevant to sensitive structures outside of the treatment field (e.g., gonads, fetus, and electronic implanted device such as cardiac pacemaker and/or defibrillator) and the ability to determine the dose to these structures Special Procedures 1. Small field	-			
the concept of gamma analysis) e. Performs and analyzes MLC QA measurements designed for accelerators used for IMRT; and f. Reviews individual patient-specific QA results with staff physicists and physicians 3. Performs ongoing review of treatment records (e.g., chart checks, review of treatment or setup images), including verification of delivered treatments 4. Demonstrates an understanding of the following components of an in vivo dosimetry program: a. Acceptance, commissioning, calibration, and ongoing quality assurance procedures for in vivo dosimetry systems b. Use of in vivo dosimetry systems for patient-specific measurement c. Limitations of specific in vivo dosimetry systems 5. Demonstrates familiarity with the dose limits relevant to sensitive structures outside of the treatment field (e.g., gonads, fetus, and electronic implanted device such as cardiac pacemaker and/or defibrillator) and the ability to determine the dose to these structures Special Procedures 1. Small field	·			
e. Performs and analyzes MLC QA measurements designed for accelerators used for IMRT; and f. Reviews individual patient-specific QA results with staff physicists and physicians 3. Performs ongoing review of treatment records (e.g., chart checks, review of treatment or setup images), including verification of delivered treatments 4. Demonstrates an understanding of the following components of an in vivo dosimetry program: a. Acceptance, commissioning, calibration, and ongoing quality assurance procedures for in vivo dosimetry systems b. Use of in vivo dosimetry systems for patient-specific measurement c. Limitations of specific in vivo dosimetry systems 5. Demonstrates familiarity with the dose limits relevant to sensitive structures outside of the treatment field (e.g., gonads, fetus, and electronic implanted device such as cardiac pacemaker and/or defibrillator) and the ability to determine the dose to these structures Special Procedures 1. Small field				
measurements designed for accelerators used for IMRT; and f. Reviews individual patient-specific OA results with staff physicists and physicians 3. Performs ongoing review of treatment records (e.g., chart checks, review of treatment or setup images), including verification of delivered treatments 4. Demonstrates an understanding of the following components of an in vivo dosimetry program: a. Acceptance, commissioning, calibration, and ongoing quality assurance procedures for in vivo dosimetry systems for patient-specific measurement c. Limitations of specific in vivo dosimetry systems for patient-specific measurement c. Limitations of specific in vivo dosimetry systems 5. Demonstrates familiarity with the dose limits relevant to sensitive structures outside of the treatment field (e.g., gonads, fetus, and electronic implanted device such as cardiac pacemaker and/or defibrillator) and the ability to determine the dose to these structures Special Procedures 1. Small field				
accelerators used for IMRT; and f. Reviews individual patient-specific OA results with staff physicists and physicians 3. Performs ongoing review of treatment records (e.g., chart checks, review of treatment or setup images), including verification of delivered treatments 4. Demonstrates an understanding of the following components of an in vivo dosimetry program: a. Acceptance, commissioning, calibration, and ongoing quality assurance procedures for in vivo dosimetry systems b. Use of in vivo dosimetry systems for patient-specific measurement c. Limitations of specific in vivo dosimetry systems 5. Demonstrates familiarity with the dose limits relevant to sensitive structures outside of the treatment field (e.g., gonads, fetus, and electronic implanted device such as cardiac pacemaker and/or defibrillator) and the ability to determine the dose to these structures Special Procedures 1. Small field	· ·			
f. Reviews individual patient-specific OA results with staff physicists and physicians 3. Performs ongoing review of treatment records (e.g., chart checks, review of treatment or setup images), including verification of delivered treatments 4. Demonstrates an understanding of the following components of an in vivo dosimetry program: a. Acceptance, commissioning, calibration, and ongoing quality assurance procedures for in vivo dosimetry systems b. Use of in vivo dosimetry systems for patient-specific measurement c. Limitations of specific in vivo dosimetry systems 5. Demonstrates familiarity with the dose limits relevant to sensitive structures outside of the treatment field (e.g., gonads, fetus, and electronic implanted device such as cardiac pacemaker and/or defibrillator) and the ability to determine the dose to these structures Special Procedures 1. Small field	_			
QA results with staff physicists and physicians 3. Performs ongoing review of treatment records (e.g., chart checks, review of treatment or setup images), including verification of delivered treatments 4. Demonstrates an understanding of the following components of an in vivo dosimetry program: a. Acceptance, commissioning, calibration, and ongoing quality assurance procedures for in vivo dosimetry systems b. Use of in vivo dosimetry systems for patient-specific measurement c. Limitations of specific in vivo dosimetry systems 5. Demonstrates familiarity with the dose limits relevant to sensitive structures outside of the treatment field (e.g., gonads, fetus, and electronic implanted device such as cardiac pacemaker and/or defibrillator) and the ability to determine the dose to these structures Special Procedures 1. Small field				
physicians 3. Performs ongoing review of treatment records (e.g., chart checks, review of treatment or setup images), including verification of delivered treatments 4. Demonstrates an understanding of the following components of an in vivo dosimetry program: a. Acceptance, commissioning, calibration, and ongoing quality assurance procedures for in vivo dosimetry systems b. Use of in vivo dosimetry systems for patient-specific measurement c. Limitations of specific in vivo dosimetry systems 5. Demonstrates familiarity with the dose limits relevant to sensitive structures outside of the treatment field (e.g., gonads, fetus, and electronic implanted device such as cardiac pacemaker and/or defibrillator) and the ability to determine the dose to these structures Special Procedures 1. Small field	1			
3. Performs ongoing review of treatment records (e.g., chart checks, review of treatment or setup images), including verification of delivered treatments 4. Demonstrates an understanding of the following components of an in vivo dosimetry program: a. Acceptance, commissioning, calibration, and ongoing quality assurance procedures for in vivo dosimetry systems b. Use of in vivo dosimetry systems for patient-specific measurement c. Limitations of specific in vivo dosimetry systems 5. Demonstrates familiarity with the dose limits relevant to sensitive structures outside of the treatment field (e.g., gonads, fetus, and electronic implanted device such as cardiac pacemaker and/or defibrillator) and the ability to determine the dose to these structures Special Procedures 1. Small field	* *			
treatment records (e.g., chart checks, review of treatment or setup images), including verification of delivered treatments 4. Demonstrates an understanding of the following components of an in vivo dosimetry program: a. Acceptance, commissioning, calibration, and ongoing quality assurance procedures for in vivo dosimetry systems b. Use of in vivo dosimetry systems for patient-specific measurement c. Limitations of specific in vivo dosimetry systems 5. Demonstrates familiarity with the dose limits relevant to sensitive structures outside of the treatment field (e.g., gonads, fetus, and electronic implanted device such as cardiac pacemaker and/or defibrillator) and the ability to determine the dose to these structures Special Procedures 1. Small field				
checks, review of treatment or setup images), including verification of delivered treatments 4. Demonstrates an understanding of the following components of an in vivo dosimetry program: a. Acceptance, commissioning, calibration, and ongoing quality assurance procedures for in vivo dosimetry systems b. Use of in vivo dosimetry systems for patient-specific measurement c. Limitations of specific in vivo dosimetry systems 5. Demonstrates familiarity with the dose limits relevant to sensitive structures outside of the treatment field (e.g., gonads, fetus, and electronic implanted device such as cardiac pacemaker and/or defibrillator) and the ability to determine the dose to these structures Special Procedures 1. Small field				
images), including verification of delivered treatments 4. Demonstrates an understanding of the following components of an in vivo dosimetry program: a. Acceptance, commissioning, calibration, and ongoing quality assurance procedures for in vivo dosimetry systems b. Use of in vivo dosimetry systems for patient-specific measurement c. Limitations of specific in vivo dosimetry systems 5. Demonstrates familiarity with the dose limits relevant to sensitive structures outside of the treatment field (e.g., gonads, fetus, and electronic implanted device such as cardiac pacemaker and/or defibrillator) and the ability to determine the dose to these structures Special Procedures 1. Small field	,			
delivered treatments 4. Demonstrates an understanding of the following components of an in vivo dosimetry program: a. Acceptance, commissioning, calibration, and ongoing quality assurance procedures for in vivo dosimetry systems b. Use of in vivo dosimetry systems for patient-specific measurement c. Limitations of specific in vivo dosimetry systems 5. Demonstrates familiarity with the dose limits relevant to sensitive structures outside of the treatment field (e.g., gonads, fetus, and electronic implanted device such as cardiac pacemaker and/or defibrillator) and the ability to determine the dose to these structures Special Procedures 1. Small field	-			
4. Demonstrates an understanding of the following components of an in vivo dosimetry program: a. Acceptance, commissioning, calibration, and ongoing quality assurance procedures for in vivo dosimetry systems b. Use of in vivo dosimetry systems for patient-specific measurement c. Limitations of specific in vivo dosimetry systems 5. Demonstrates familiarity with the dose limits relevant to sensitive structures outside of the treatment field (e.g., gonads, fetus, and electronic implanted device such as cardiac pacemaker and/or defibrillator) and the ability to determine the dose to these structures Special Procedures 1. Small field				
the following components of an in vivo dosimetry program: a. Acceptance, commissioning, calibration, and ongoing quality assurance procedures for in vivo dosimetry systems b. Use of in vivo dosimetry systems for patient-specific measurement c. Limitations of specific in vivo dosimetry systems 5. Demonstrates familiarity with the dose limits relevant to sensitive structures outside of the treatment field (e.g., gonads, fetus, and electronic implanted device such as cardiac pacemaker and/or defibrillator) and the ability to determine the dose to these structures Special Procedures 1. Small field				
a. Acceptance, commissioning, calibration, and ongoing quality assurance procedures for <i>in vivo</i> dosimetry systems b. Use of <i>in vivo</i> dosimetry systems for patient-specific measurement c. Limitations of specific <i>in vivo</i> dosimetry systems 5. Demonstrates familiarity with the dose limits relevant to sensitive structures outside of the treatment field (e.g., gonads, fetus, and electronic implanted device such as cardiac pacemaker and/or defibrillator) and the ability to determine the dose to these structures Special Procedures 1. Small field	_			
a. Acceptance, commissioning, calibration, and ongoing quality assurance procedures for in vivo dosimetry systems b. Use of in vivo dosimetry systems for patient-specific measurement c. Limitations of specific in vivo dosimetry systems 5. Demonstrates familiarity with the dose limits relevant to sensitive structures outside of the treatment field (e.g., gonads, fetus, and electronic implanted device such as cardiac pacemaker and/or defibrillator) and the ability to determine the dose to these structures Special Procedures 1. Small field				
calibration, and ongoing quality assurance procedures for <i>in vivo</i> dosimetry systems b. Use of <i>in vivo</i> dosimetry systems for patient-specific measurement c. Limitations of specific <i>in vivo</i> dosimetry systems 5. Demonstrates familiarity with the dose limits relevant to sensitive structures outside of the treatment field (e.g., gonads, fetus, and electronic implanted device such as cardiac pacemaker and/or defibrillator) and the ability to determine the dose to these structures Special Procedures 1. Small field				
assurance procedures for in vivo dosimetry systems b. Use of in vivo dosimetry systems for patient-specific measurement c. Limitations of specific in vivo dosimetry systems 5. Demonstrates familiarity with the dose limits relevant to sensitive structures outside of the treatment field (e.g., gonads, fetus, and electronic implanted device such as cardiac pacemaker and/or defibrillator) and the ability to determine the dose to these structures Special Procedures 1. Small field	_			
dosimetry systems b. Use of in vivo dosimetry systems for patient-specific measurement c. Limitations of specific in vivo dosimetry systems 5. Demonstrates familiarity with the dose limits relevant to sensitive structures outside of the treatment field (e.g., gonads, fetus, and electronic implanted device such as cardiac pacemaker and/or defibrillator) and the ability to determine the dose to these structures Special Procedures 1. Small field				
b. Use of in vivo dosimetry systems for patient-specific measurement c. Limitations of specific in vivo dosimetry systems 5. Demonstrates familiarity with the dose limits relevant to sensitive structures outside of the treatment field (e.g., gonads, fetus, and electronic implanted device such as cardiac pacemaker and/or defibrillator) and the ability to determine the dose to these structures Special Procedures 1. Small field	- The state of the			
for patient-specific measurement c. Limitations of specific in vivo dosimetry systems 5. Demonstrates familiarity with the dose limits relevant to sensitive structures outside of the treatment field (e.g., gonads, fetus, and electronic implanted device such as cardiac pacemaker and/or defibrillator) and the ability to determine the dose to these structures Special Procedures 1. Small field	·			
c. Limitations of specific in vivo dosimetry systems 5. Demonstrates familiarity with the dose limits relevant to sensitive structures outside of the treatment field (e.g., gonads, fetus, and electronic implanted device such as cardiac pacemaker and/or defibrillator) and the ability to determine the dose to these structures Special Procedures 1. Small field				
dosimetry systems 5. Demonstrates familiarity with the dose limits relevant to sensitive structures outside of the treatment field (e.g., gonads, fetus, and electronic implanted device such as cardiac pacemaker and/or defibrillator) and the ability to determine the dose to these structures Special Procedures 1. Small field				
5. Demonstrates familiarity with the dose limits relevant to sensitive structures outside of the treatment field (e.g., gonads, fetus, and electronic implanted device such as cardiac pacemaker and/or defibrillator) and the ability to determine the dose to these structures Special Procedures 1. Small field	-			
dose limits relevant to sensitive structures outside of the treatment field (e.g., gonads, fetus, and electronic implanted device such as cardiac pacemaker and/or defibrillator) and the ability to determine the dose to these structures Special Procedures 1. Small field	dosimetry systems			
structures outside of the treatment field (e.g., gonads, fetus, and electronic implanted device such as cardiac pacemaker and/or defibrillator) and the ability to determine the dose to these structures Special Procedures 1. Small field	-			
field (e.g., gonads, fetus, and electronic implanted device such as cardiac pacemaker and/or defibrillator) and the ability to determine the dose to these structures Special Procedures 1. Small field				
electronic implanted device such as cardiac pacemaker and/or defibrillator) and the ability to determine the dose to these structures Special Procedures 1. Small field				
cardiac pacemaker and/or defibrillator) and the ability to determine the dose to these structures Special Procedures 1. Small field				
defibrillator) and the ability to determine the dose to these structures Special Procedures 1. Small field	·			
determine the dose to these structures Special Procedures 1. Small field	1			
Special Procedures 1. Small field	1			
Special Procedures 1. Small field				
1. Small field	structures			
	Special Procedures			
a. Stereotactic radiosurgery (SRS)	1. Small field			
	a. Stereotactic radiosurgery (SRS)			

		1	_	
i.	Explains rationales for SRS			
	treatments, examples of malignant			
	and non-malignant lesions			
	treated with SRS, and typical			
	dose and fractionation schemes			
	for linac-based and Co-60 SRS			
	techniques			
ii.	Describes in general terms the			
	components of commissioning an			
	SRS sys-tem (e.g., accurate			
	localization, mechanical precision,			
	accurate and optimal dose			
	distribution, and patient safety)			
iii.	Explains the stereotactic			
	localization of a target (e.g., on			
	the basis of angiography as			
	opposed to CT and MRI) and how			
	the accuracy of this localization is			
	measured			
iv.	Describes the alignment of			
	coordinate systems (e.g., target			
	frame of reference with linac			
	frame of reference) and how the			
	mechanical precision of this			
	alignment is measured			
٧.	Describes issues associated with			
	dosimetry measurements for an SRS			
	system (e.g., choice of dosimeter,			
	phantom geometry, etc.)			
vi.	Describes the components of pre-			
	treatment QA for an SRS system,			
	including linac-based and Co-60			
	SRS techniques			
b. S	tereotactic body radiation therapy			
(5	SBRT)			
i.	Explains the rationale for SBRT			
	treatments, common treatment			
	sites, and typical dose and			
	fractionation schemes			
ii.	Describes immobilization and			
	localization systems for SBRT			
1	treatments			
iii.	Describes the use of simulation			
1	imaging for SBRT target definition,			
	including multi-modality imaging			
	and 4D imaging for cases			
	requiring motion management			
iv.	Describes treatment planning			
'*-	objectives for SBRT treatments,			
1	including dose limits, dose			
	heterogeneity, dose gradient			
	and fall-off, and beam geometry			
Ь	and fair on, and beam geometry	1	I	

v. Describe	s treatment verification				
and deliv	ery for SBRT treatments				
as well as	s use of in-room imaging				
vi. Describe	s the need for motion				
managen	nent in lung and				
abdomer	SBRT treatments				
vii. Describe	s treatment planning				
system va	alidation tests, and in this				
context,	tissue inhomogeneity				
correctio	ns and small-field				
dosimetr	y measurements				
	-				
2. Total body	(photon) irradiation (TBI)				
a. Describe	s the rationale for TBI				
treatmer	nts for the treatment of				
malignan	it and benign conditions				
b. Demonst	rates an understanding of				
TBI presci	ription and delivery				
technique	es and of issues related to				
the clinic	al commissioning and				
maintena	nce of a TBI program				
c. Describe	s and demonstrates an				
understa	nding of the significance of				
beam mo	odifiers commonly used				
during T	BI treatments (e.g.,				
lung/kidi	ney blocks, beam spoilers)				
d. Participa	tes in all aspects of TBI				
treatmer	nt (i.e., simulation,				
planning,	plan verification,				
treatmer	nt, treatment verification,				
and in vi	vo measurements). NOTE:				
This com	petency is optional.				
3. Total skin e	lectron treatment (TSET)				
	s the rationale of TSET				
	its for the treatment of				
	t and benign conditions				
	trates an understanding				
	delivery techniques and				
	related to the clinical				
	oning and maintenance of				
a TSET pr					
-	the significance of the B-				
factor					
d. Describe	s and demonstrates an				
	nding of the significance of				
beam mo	odifiers commonly used				
	SET treatments (e.g.,				
shields, b	eam scatter); and				
e. Participa	tes in all aspects of TSET				
treatmer	nt (i.e., simulation,				
		1	I	1	<u>l</u>

	· · · · · · · · · · · · · · · · · · ·	<u>-</u>	
planning, plan verification,			
treatment, treatment			
verification, and in vivo			
measurements). NOTE: This			
competency is optional.			
4. Respiratory-correlated planning and			
delivery			
a. Describes the rationale for using			
respiratory management systems			
in radiation therapy			
b. Describes the common issues			
introduced by respiratory motion in			
imaging, planning, and treatment			
delivery			
c. Describes common treatment sites			
affected by respiratory motion and			
the typical range of tumor			
excursion			
d. Describes methods for evaluating			
and managing respiratory motion			
e. Describes QA tests for common			
respiratory management systems			
and their recommended frequency			
Treatment Planning			
Workstations			
workstations			
1. Data acquisition			
a. Explains the connection between			
linac commissioning and the data			
required for operation of a			
treatment planning system			
b. For a particular treatment			
planning system, describes the			
linac data needed for:			
i. Photon beams			
ii. Electron beams			
iii. IMRT and VMAT			
2. Acceptance testing			
a. Describes what tests of the treatment			
planning system need to be performed			
before patient-specific planning can			
commence for:			
i. Photon beams			
	<u> </u>		

	T	T	Т	
ii. Electron beams, and				
iii. Brachytherapy sources				
3. Quality assurance				
a. Describes the tests that need to be performed and their accuracy				
b. Describes accuracy checks for the following input devices and types of images:				
i. Digitizers				
ii. Film scanners				
iii. Imported images from instruments such as CT scanners, MRI scanners, and picture archiving and communication (PAC) systems				
c. Describes accuracy checks for the following output devices:				
i. Printers				
ii. Record and verify systems				
iii. DICOM output				
4. Computer algorithms (models)				
a. Describes how the computer algorithm calculates dose for at least one major treatment planning system with regard to:				
i. Photon beams				
ii. Electron beams				
iii. Brachytherapy calculations, and				
iv. Proton beams (Optional)				
b. Describes the advantages and disadvantages of the various treatment planning calculation algorithms				

c. Describes how the computer			
algorithm determines the number			
of monitor units per beam or			
segment (for step-and-shoot IMRT)			
segment (for step-and-shoot nivita)			
5. Plan normalization			
a. Describes the numerous			
normalization capabilities available			
on a treatment planning system			
b. Describes how different			
normalization schemes affect final			
isodose curve representation			
c. Describes how the computer			
plan normalization relates to the			
calculation of monitor units for			
patient treatments			
6. Inhomogeneity (heterogeneity)			
corrections			
a. Describes the type of data that			
need to be taken on a CT scanner			
in preparation for treatment			
planning using inhomogeneous			
material			
b. Describes how these CT data are			
converted into inhomogeneity data			
usable in a treatment planning			
system			
c. Describes how computerized			
treatment planning systems take			
inhomogeneities into account			
d. Identifies where the computer			
algorithm calculates dose with			
acceptable accuracy and in which			
regions calculational accuracy is			
suspect			
e. Describes how the accuracy of			
the inhomogeneity corrections			
performed by a treatment			
planning system would be checked			
pianning system would be checked	-		
7. Beam modeling			
a. Completely models at least one		 	
photon beam energy for a			
treatment planning system			
b. Completely models at least one			
electron beam energy for a			
treatment planning system			
c. Completely models at least one			
proton beam energy for a			
treatment planning system			
(optional)			

		-	
d. Tests the accuracy of his or her			
modeling for the beams and is			
able to describe the criteria for			
acceptability of the modeling	<u> </u>		
8. Imaging tests			
a. Describes the tests that would be			
performed to ensure that the			
imported image data are correct			
b. Demonstrates that images can be			
imported from CT, MR, and PET or			
PET/CT scanners			
c. Demonstrates that the above			
imaging sets can be accurately fused			
with the primary treatment			
planning image set			
d. Describes the different image fusion			
algorithms available on a			
treatment-planning system (e.g.,			
CT-CT, CT-MR, CT-PET)			
9. Secondary monitor unit check			
computer programs			
a. Describes what input data need to			
be acquired			
b. Describes the checks of that input			
data that need to be performed to			
ensure that the monitor unit check			
program is working correctly			
c. Describes how imported data from			
treatment-planning systems are			
handled in a monitor unit check			
program			
d. Describes how the monitor unit			
check program calculates the			
number of monitor units for off			
central-axis normalization points			
e. Describes how the monitor unit			
check program calculates monitor			
units for treatments involving			
inhomogeneous material			
Patient Safety			
1. General			
a. Understands the principles behind			
the development of a general			
patient and staff safety			
management program within the			
hospital			
•			

b. Describes the physicist's role in		
developing and overseeing an		
overall quality assurance program		
for both equipment and		
procedures, including a discussion		
of allocation and management of		
resources necessary to carry out		
these tasks, incorporation of tools		
and techniques into these tasks,		
and inclusion of various groups		
within the structure of the		
radiation oncology department		
c. Describes the principles and		
rationale of TJC Universal Protocol		
as well as the use of pre-		
procedure verification and time-		
outs for the prevention of		
treatment errors		
d. Describes internal, voluntary, and		
mandatory incident reporting systems and the role of root cause		
analysis (RCA) as a tool for		
continuous quality improvement		
e. Describes the concept of a failure		
mode and effect analysis (FMEA),		
design and implementation of an		
FMEA, and how to use the results		
of such an analysis to prevent		
errors and minimize risks to		
patients and staff		
f. Describes charting systems for the		
prescription, delivery, and		
recording of treatment		
information, standardization of		
such systems, and the use of such		
systems within a record and verify		
electronic medical record system		
g. Describes mechanisms for		
independent checking of treatment		
information		
2. Equipment		
z. Equipment		
a. Describes the implementation of		
an effective set of equipment		
operating procedures that would		
include preventative maintenance		
and repair, keeping of maintenance		
and repair records, emergency		
procedures, and systematic		
inspection of interlock systems		

	•	ı	1	
b. Describes the development of a				
program to prevent mechanical				
injury caused by the machine or				
accessory equipment, with				
consideration of the need for				
visual and audio contact with the				
patient while the patient is under				
treatment				
c. Understands potential patient				
safety hazards related to the use				
of blocks, block trays, wedges, and				
other ancillary treatment devices				
and accessories as well as				
mechanisms to minimize these				
risks				
d. Understands potential patient				
safety hazards posed by patient				
support and immobilization				
systems, as well as mechanisms to				
minimize these risks				
e. Understands potential patient				
safety hazards of gantry-patient				
collision as well as mechanisms to				
minimize this risk				
3. Other patient/staff safety issues				
a. Understands potential electrical				
hazards affecting patients and staff				
b. Understands the potential hazards				
to patients and staff posed by				
strong magnetic fields				
c. Understands the mechanisms of				
ozone production and related				
potential hazards to patients and				
staff				
d. Understands potential hazards				
to patients and staff arising				
from the use of cerrobend				